Luxa biotechnology announces publication in cell stem cell describing positive clinical results for first-in-human clinical trial for dry amd therapy

Fort lee, n.j.--(business wire)--luxa biotechnology llc (luxa), a clinical-stage biotechnology company developing novel adult retinal pigment epithelial stem cell (rpesc) therapies for dry age-related macular degeneration (dry amd), today announced the publication of phase 1/2a clinical trial results in a paper titled "safety and tolerability of rpe stem cell-derived rpe transplantation in patients with dry age-related macular degeneration: low dose clinical outcomes" in the journal cell stem c.
AMD Ratings Summary
AMD Quant Ranking